
Reinventing Drug Discovery: Dermot Tierney on AI, Evolution, and Building AMPLY
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
このコンテンツについて
In this episode of Venture Recap, Matt Oguz sat down with Dermot Tierney, co-founder and COO of AMPLY Discovery, a groundbreaking company reimagining drug discovery at the intersection of AI, synthetic biology, and evolutionary science.
Dermot shares how AMPLY’s platform, AMPLYfolioAI, leverages nature’s own R&D engine—evolution—to find novel molecules that can fight cancer, drug-resistant infections, and more. We explore the company's unique "drug discovery studio" model, how it's flipping traditional biotech economics, and why the next generation of therapeutics might come from the genomic dark matter of frogs, fungi, and everything in between.
We also dive into Dermot's experience transitioning from university tech transfer to full-time founder, and how his commercialization mindset is helping AMPLY scale faster, smarter, and more impactfully.
Whether you're interested in deep tech, biotech, or what’s next in AI-powered healthcare, this episode is packed with insight, optimism, and practical takeaways.
It is essential that listeners conduct their own thorough research and consult with a qualified financial, legal, or tax professional before making any investment decisions. This podcast does not offer financial, legal, or tax advice, nor does it recommend any specific investments. Investment involves risk your investment. AI tools may be used in creation or edits of this podcast. The information presented here may not be complete or accurate, and no warranties are provided. Past results do not guarantee future performance in any case.